Higher risk of cardiac arrhythmia and death with azithromycin and levofloxcin, compared with amoxicillin
Following the 2013 Food and Drug Administration warning on azithromycin use and the risk of potential fatal heart rhythms, researchers in South Carolina evaluate a national cohort of veterans receiving care at the Department of Veterans Affairs to investigate whether cardiac arrhythmia and mortality risks are observed in older male patients receiving azithromycin, amoxicillin and levofloxacin. Analysis of more than 1. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - March 12, 2014 Category: Consumer Health News Tags: Cardiovascular / Cardiology Source Type: news
Can Antibiotics Trigger Arrhythmias?
(MedPage Today) -- Azithromycin and levofloxacin were both associated with elevated risks of death and serious cardiac arrhythmias during standard lengths of prescription, a study of mostly male military veterans showed. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - March 11, 2014 Category: Cardiology Source Type: news
Azithromycin, Levofloxacin Linked to Increased Risks for Arrhythmia and Mortality Compared with Amoxicillin (FREE)
By Amy Orciari Herman Azithromycin and levofloxacin carry higher arrhythmia and mortality risks than amoxicillin, according to an observational study in the Annals of Family Medicine. The FDA issued a cardiac warning … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - March 11, 2014 Category: Primary Care Source Type: news
Cardiac Risks With Antibiotics Supported by VA DataCardiac Risks With Antibiotics Supported by VA Data
The data also showed the antibiotic levofloxacin was associated with a significantly increased risk of death and cardiac arrhythmia when compared with patients treated with amoxicillin. Heartwire (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - March 10, 2014 Category: Cardiology Tags: Cardiology News Source Type: news
McSweeney / Langevin Providing Legal Advice in Response to Alleged...
The law firm McSweeney / Langevin is investigating retinal detachment claims allegedly caused by Levaquin. McSweeney / Langevin's legal investigation follows the Food and Drug...(PRWeb August 29, 2013)Read the full story at http://www.prweb.com/releases/2013/8/prweb11067398.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - August 31, 2013 Category: Pharmaceuticals Source Type: news
Risk Of Kidney Disease Doubled With Use Of Fluoroquinolone Antibiotics
The risk of acute kidney disease is doubled for people taking oral fluoroquinolone antibiotics, according to a study of published in CMAJ (Canadian Medical Association Journal). Fluoroquinolones, including ciprofloxacin, levofloxacin and moxifloxacin, are common broad-spectrum antibiotics most often used to treat respiratory and urogenital infections. Case reports have indicated acute kidney injury with use, and prescription labels carry a warning of kidney failure. However, when oral fluoroquinolones are prescribed in clinical practice, kidney injury is usually not considered... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - June 3, 2013 Category: Consumer Health News Tags: Urology / Nephrology Source Type: news
Title: levofloxacin, LevaquinCategory: MedicationsCreated: 4/3/1999 1:39:00 PMLast Editorial Review: 4/5/2013 12:00:00 AM (Source: MedicineNet Hepatitis C General)
Source: MedicineNet Hepatitis C General - April 5, 2013 Category: Infectious Diseases Source Type: news
Horizin scanning: Two phase III studies show promise for levofloxacin solution for inhalation in patients with cystic fibrosis and chronic lung infection
Source: BioSpace.com Area: News BioSpace has reported that results from two phase III studies have shown that levofloxacin inhalation solution was effective and improved lung function in patients with cystic fibrosis who had previously been heavily pretreated with inhaled antibiotics prior to enrollment. In one Phase 3 study (Study 207) conducted in 330 patients, inhaled levofloxacin delivered by a customised nebuliser at a dose of 240 mg twice daily, was compared to placebo in a double-blind, randomised single treatment-cycle of 28 days. In the second Phase 3 study (Study 209) conducted in 282 patients, the sa...
Source: NeLM - News - January 8, 2013 Category: Drugs & Pharmacology Source Type: news